Skip to main content
Premium Trial:

Request an Annual Quote

CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests

NEW YORK (GenomeWeb) – CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring.

Under the agreement, CellMax will combine its technology for CTC isolation with IncellDx’s proprietary BioINK microfluidic reagents. Tests will be processed at CellMax's CLIA lab in Sunnyvale, California and will be jointly marketed in the US by its sales force.

Additional terms of the agreement were not disclosed.

CellMax CEO Atul Sharan said in a statement that IncellDx's reagent platform will bring "tremendous added value" to its tests. The first project will be to commercialize a blood-based PD-L1 assay based on analysis of both RNA and protein in captured CTCs, to be used in immunotherapy selection and monitoring.

The first generation of tests developed to measure PD-L1 required a biopsy sample of a patient's tumor. Because blood-based testing is less invasive, easier, and can be performed repeatedly, it offers potential advantages over available assays.

CellMax and IncellDx intend to present performance data for their CTC-based PD-L1 test in non-small cell lung cancer at the annual meeting of the American Association for Cancer Research later this month.

According to the companies, the CellMax technology has been able to capture CTCs for PD-L1 testing in about 90 percent of patients across all stages of NSCLC, with about 50 percent testing PD-L1 positive.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.